Limitations of current therapy
Current treatment regimens for blood clots, both in the acute phase and as a preventive treatment, are drugs that inhibit blood coagulation and / or platelets. All current treatment leads to a constant light bleeding condition of the patient that is associated with serious side effects such as bleeding complications. Because of the risk of bleeding complications, these drugs cannot be used in high enough doses or not at all to provide optimal protection against blood clots. This results in the patient, despite the given treatment, continues to have a high risk of blood clots.
In healthy individuals, the body can regulate the development of blood clots very precisely so that they are limited to just repairing vascular damage in order to prevent or quickly stop the bleeding without clogging the blood vessel. This is done by the regulation of both clot-forming and degradation. In individuals with risk factors for heart attack and stroke (such as diabetes, obesity and high blood pressure), this balance is disrupted and individuals have an overactivity of the clot-forming system and little to no activity of the thrombolytic system.
This is a major clinical problem in healthcare today. Many of the patients who have the greatest risk of developing blood clots are also those who are most fragile and have the greatest risk of bleeding complications. This means that many patients who need “blood-thinning” medications do not get such at all or too low a dose, due to the risk of bleeding complications being deemed too high. Suboptimal doses of antithrombotic agents therefore provide insufficient protection against blood clots, which means that the number of cases of stroke or heart attack is more than with effective therapy while there is a significantly increased risk of major bleeding complications during the often life-long treatment with these drugs.